| Document |
Document Title |
|
WO/2011/100608A1 |
The patent application relates to a method of producing a monomer component from a genetically modified polyhydroxyalkanoate (PHA) biomass, wherein the biomass is heated in the presence of a catalyst to release a monomer component from t...
|
|
WO/2011/095050A1 |
Disclosed are C-glycoside sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors containing saturated 6-member rings shown as following general formula I, preparation methods, compositions containing such compounds and uses thereof ...
|
|
WO/2011/095434A1 |
The present invention relates to a compound of general formula (I) wherein X is -O- or -CH2-; X' is -O- or -CH2-; with the proviso that one of X or X' is always -O- and the other is -CH2-.It has been found that the compounds of general f...
|
|
WO/2011/091778A1 |
The invention relates to a compound of the general structure (I), where R is a hydrogen atom (H) or an unsubstituted, monosubstituted, or polysubstituted C1-C20 alkyl, wherein the alkyl can be straight, branched, cyclic, or partially uns...
|
|
WO/2011/092611A1 |
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...
|
|
WO/2011/091710A1 |
Disclosed are sodium dependent glucose cotransporter inhibitors II with the phenyl C-glucoside structure, their preparation methods, the pharmaceutical compositions containing them, the uses of treating diabetes and manufacturing a medic...
|
|
WO/2011/088015A1 |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
WO/2011/081083A1 |
Provided are a neuraminic acid derivative, which selectively inhibits virus sialidase activity but little inhibits human sialidase activity, a sialidase activity inhibitor, and an antiinfluenza drug. The aforesaid neuraminic acid derivat...
|
|
WO/2011/071259A2 |
The present invention provides a method for culturing cells, which is able to prevents the possibility of mycoplasma contamination by culturing the cells using biomass extract obtained by culturing a strain with amphidinol productivity, ...
|
|
WO/2011/068560A1 |
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
|
|
WO/2011/068561A1 |
Disclosed are compounds (I) which inhibit the activity of anti-apoptotic Bc1-2 or Bc1 xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti apoptotic Bc1-2 protein.
|
|
WO/2011/064303A1 |
The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but al...
|
|
WO/2011/060742A1 |
Methods for preparing statin compounds by lactonization are disclosed, which comprise the following step: lactonizing compounds of formula II into compounds of formula I in the presence of strong acid catalyst and dehydrator in the first...
|
|
WO/2011/053048A2 |
The present invention relates to a novel vascular leak inhibitor. The novel vascular leak inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by V...
|
|
WO/2011/053948A1 |
The present invention relates to compounds of the formula (I) wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the end...
|
|
WO/2011/048554A2 |
The present invention relates to the cosmetic use of a combination including a lysate of at least one probiotic microorganism of the Bifidobacterium sp. genus having at least one C-glycoside derivative as an active agent that can be used...
|
|
WO/2011/048148A2 |
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...
|
|
WO/2011/045478A1 |
The present invention relates to substrates coated with films including compounds having the following generic formula (I): formula (I) as well as the manufacturing method thereof and the use of same as an anode interfacial layer in elec...
|
|
WO/2011/043272A1 |
Disclosed are: a ligand for an asymmetric synthesis catalyst; and a process for producing an α-alkenyl cyclic compound using the ligand. Specifically disclosed are: a ligand for an asymmetric synthesis catalyst, which is represented by ...
|
|
WO/2011/040509A1 |
In order to provide a low molecular weight compound that has p38MAPK inhibitory activity and the accompanying TNFα production suppression activity and that has a favorable pharmacokinetic profile as a pharmaceutical and decreased hepato...
|
|
WO/2011/038926A1 |
A process for the protection of a compound having at least one reactive functional group selected from hydroxy, mercapto, carboxyl, amino and amide, with 3,4-dihydro-2H-pyran (DΗP), wherein said DΗP is obtained by contacting tetrahydro...
|
|
WO/2011/038910A1 |
The present invention relates to a process for the preparation of 2,3-dihydropyran (DHP, CAS [110-87-2]) and its use in industrial chemistry.
|
|
WO/2011/034078A1 |
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...
|
|
WO/2011/030160A1 |
A method for determining the presence of mycobacteria species in an organism or biological sample, the method comprising adding to the organism or biological sample a probe molecule comprising a substrate and a label, which probe molecul...
|
|
WO/2011/030591A1 |
Disclosed is a novel zinc cluster compound represented by general formula (1): Zn4O(OCOR)6(RCOOH)n, wherein R represents an alkyl group which has 1 to 4 carbon atoms and may be substituted with a halogen atom, and n represents 0.1 to 1, ...
|
|
WO/2010/136431A9 |
The present invention provides compounds of formula (I) wherein the substituents are as defined in claim 1. The compounds are suitable intermediates in the preparation of herbicidally active 4-phenyl-3,5-pyrandiones, 4-phenyl-3,5-thiopyr...
|
|
WO/2011/027888A1 |
Disclosed are a diamide-phenyl derivative which inhibits soluble epoxy hydrolase (sEH), and a pharmaceutically acceptable salt of the diamide-phenyl derivative. Specifically disclosed are a compound represented by formula (I), and a phar...
|
|
WO/2011/021534A1 |
Provided are liquid crystal compounds which have large negative permittivity anisotropy and combine a high clearing point and a low viscosity and which further have at least one other characteristic such as heat or light stability, prope...
|
|
WO/2011/014008A2 |
The present invention relates to novel 3-phenoxy-4-pyrone, 3-phenoxy-4-pyridone, or 4-pyridone derivatives, or to pharmaceutically acceptable salts thereof, to a method for preparing same, and to an antibacterial composition containing s...
|
|
WO/2011/006208A1 |
The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents.
|
|
WO/2011/003976A1 |
The present invention relates to a crystallisation procedure to obtain 1 -(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thie
nylmethyl] benzene hemihydrate crystals having a narrow particle size distribution and improved flowabi...
|
|
WO/2010/151644A2 |
Disclosed is a general methodology to create nano fibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reacti...
|
|
WO/2010/145788A1 |
The present invention relates to propargyloxybenzamide derivatives, their processes of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic ...
|
|
WO/2010/145789A1 |
The present invention relates to propargyloxybenzamide derivatives, their processes of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic ...
|
|
WO/2010/142650A1 |
The invention relates to compounds of formula (I) wherein A1, R1, R2, R3, R4 and R5 are defined in the description and in the claims, which are preferential inhibitors of the cysteine protease cathepsin, in particular of the cysteine pro...
|
|
WO/2010/133133A1 |
A synthetic method of 2-methyl-6-tert-butyl-4-dicyanomethylene-4H-pyran is disclosed. This method includes the following steps: (1) refluxing the solution of 2-methyl-6-tert-butyl-pyrone and malononitrile in acetic anhydride, monitoring ...
|
|
WO/2010/133473A1 |
The present invention relates to a method for producing 2-substituted 4-hydroxy-4-methyl tetrahydropyranoles by reacting 3-methylbut-3-en-1-ol (isoprenol) with the corresponding aldehydes in the presence of a strongly acidic cation excha...
|
|
WO/2010/133131A1 |
A synthetic method of 2-methyl-6-tert-butyl-4-dicyanomethylene-4H-pyran is disclosed. This method includes the following steps: (1). reacting pinacolone with boron trifluoride etherate to obtain 5,5-dimethyl-2,4-adipaldehyde-0,0-boron di...
|
|
WO/2010/127443A1 |
The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of...
|
|
WO/2010/128324A1 |
The present invention provides compounds of formula (I), in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
|
|
WO/2010/125466A1 |
Methods for producing amrubicin and structural analogs thereof. The present invention encompasses synthetic pathways for the production of amrubicin (Formula I) and structural analogs thereof. The synthetic pathways of the present invent...
|
|
WO/2010/123016A1 |
Disclosed is a compound having a GPR40 agonistic activity and useful for use in a pharmaceutical composition or useful as an insulin secretion promoter or a prophylactic or therapeutic agent for diabetes. Extensive studies have been made...
|
|
WO/2010/122968A1 |
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...
|
|
WO/2010/119161A2 |
The invention relates to a compound having formula (I), the hydroxyacid form thereof, the pharmaceutically acceptable salts of the hydroxyacid and prodrugs and pharmaceutically acceptable solvates of the compound and the hydroxyacid form...
|
|
WO/2010/113813A1 |
Disclosed are: a base-generating agent which has a high sensitivity and a wide application range; and a photosensitive resin composition which has a wide range of application choices owing to the structure of a polymer precursor the reac...
|
|
WO2010110409A1 |
A pyrone derivative and a pyridone derivative which are intermediates for a novel anti-influenza drug; a process for producing these derivatives; and methods of using these derivatives.
|
|
WO/2010/102848A1 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/102003A2 |
In one aspect, the invention relates to compounds which are useful as as inhibitors of glycine type 1 transporter (GIyT1) activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and met...
|
|
WO/2010/098583A2 |
The present invention relates to a novel method for preparing statin compounds or salts thereof, which are useful in treating and preventing hyperlipidemia-related diseases, and to intermediate compounds used in same. The method of the p...
|
|
WO/2010/097374A1 |
The invention relates to the compounds of the general formula (I) wherein n, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as described in the description, to enantiomers thereof, to diastereomers thereof, to mixtures and salts thereof, ...
|
